**CURRICULUM VITAE**

**Name:** Raquel Susana Cuchacovich, M.D.

**Business Address:** University of South Florida School of Medicine

Rheumatology Section

**Business Telephone and Telefax:** 813-974-2201(phone)

813-974 -5229(fax)

**E-mail Address:** rcuchaco@usf.edu

**Citizenship:** United States

**Education:**

**Undergraduate/Medical:** University of Chile 1984

Santiago, Chile

Medical Doctorate

**Research Fellowship:** LSU Health Sciences Center 1999-

Department of Medicine 2003

Section of Rheumatology

**Internship/Residency:** LSU Health Sciences Center 2003-

Internal Medicine 2006

**Clinical Fellowship:** LSU Health Sciences Center 2006-

Rheumatology 2008

University of Chile 1993

Clinical Immunology 1996

**Certification:** Specialization in Clinical Immunology 1996

University of Chile

Santiago, Chile

Certification in internal medicine 2006

American Board of Internal Medicine

Certification in rheumatology 2008

American Board of Internal Medicine

Rheumatology recertification 2018

American Board of Internal Medicine

ECFMG/USMLE:

* Basic science 2000
* Clinical science 2001
* English 2001
* Clinical skills assessment 2002

**Licensure:** State of Louisiana – #202372

Expires March 31, 2017

State of Indiana-# 01074640A

Expires October 31, 2019

State of Florida #ME 138644

Expires January 31, 2023

**Academic, Professional, and Research Appointments:**

Associate Professor of Clinical Medicine May/2019-present

University of South Florida School of Medicine

Associate Program director Rheumatology 2017- March/2019

Indiana University

Associate Professor of Clinical Medicine

Clinical Key Educator April 1/2015-March 2019

Section of Rheumatology

Department of Medicine

IU School of Medicine

Indianapolis, IN

Medical Advisor (CRP)-Autoimmune Platform Eli Lilly1/14/2013- 3/2015

Associate Professor of Clinical Medicine (Appointment) 1/12/2013 (present)

Section of Rheumatology

Department of Medicine

Louisiana State University HSC

New Orleans, Louisiana

Associate Professor of Clinical Medicine 8/2012-1/11/2013

Section of Rheumatology

Department of Medicine

Louisiana State University HSC

New Orleans, Louisiana

Assistant Professor of Clinical Medicine 7/2008-7/2012

Section of Rheumatology

Department of Medicine

Louisiana State University HSC

New Orleans, Louisiana

Post-Doctoral Research Fellow 3/1999-6/2003

Section of Rheumatology

Department of Medicine

Louisiana State University Health Sciences Center

New Orleans, Louisiana

Assistant Professor and Chief of Immunology Lab 1994-1999

Rheumatology Service

Department of Medicine

San Juan de Dios Hospital

National Public Health Service

University of Chile

Santiago, Chile

Assistant Professor 1992-1994

Department of Experimental Medicine and Pathophysiology

University of Chile

Santiago, Chile

Primary-care physician 1987-1991

Curacavi Hospital

Chile

**Membership in Professional Organizations:**

* American College of Rheumatology
* Spondyloarthropathy Research Group (SPARTAN)
* Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)

**Awards and Honors:**

* LSUHSC Research Day\* 2000
* LSUHSC Research Day 2001
* American Federation for Medical Research (AFMR) 2001

Southern Regional Meeting

* Second Place, Research Fellow 2001

AmericanCollege of Rheumatology

65th Annual Meeting

“Distinct patterns of gene expression by DNA microarray in peripheral blood mononuclear cells (PBMC) of rheumatoid arthritis (RA) and psoriatic arthritis patients treated with anti-TNF or Methotrexate (MTX)”

* LSUHSC Research Day 2002
* LSUHSC Research Day – Second Place 2003
* Ochsner Research Night 2007
* Semi-finalist 2007

National Young Rheumatology Investigator Forum

University of MississippiMedicalCenter

* Fellow Recognition Award, Clinical Fellow 2007

AmericanCollege of Rheumatology (ACR)

“Do TNF-alpha blockers play any role in cardiovascular risk among rheumatoid arthritis patients?”

* AFMR Southern Regional Meeting 2008
* LSUHSC Research Day – First Place, Poster Presentation 2010
* AFMR Southern Regional Meeting 2010

\* All Research Day awards are for either poster or oral presentations of translational research studies.

**Teaching Experience/Responsibilities:**

* Medicine Grand Rounds “Rheumatic irAEs of Immune check point inhibition” 10/2019
* Key Clinical Educator IU School of Medicine April/2015-March 2019
* ACR Knowledge Bowl 2016
* Medicine Grand Rounds 2012

“Pleiotropic effects of Inflammasome modulation in Rheumatologic Conditions and associated co-morbidities: Potential Therapeutic Implications”

LSU Health Sciences Center

New Orleans, Louisiana

* Experts in Arthritis 2012

Tulane University Medical School

* Medicine Grand Rounds 2009

“Clinical Significance of Hyperuricemia”

LSU Health Sciences Center

New Orleans, Louisiana

* Developed, supervise, and participate in the Rheumatology Core 2008-2012

Lectureship Program, a series of 32 immuno-rheumatology lectures that are one hour in duration and given weekly.

* Create and give rheumatology lectures to Medicine and Geriatrics 2008-2012

residents and third-year medical students

* Conduct clinical rounds, Case Conferences, Journal Clubs with

Rheumatology fellows, Medicine, Physical Medicine 2008-2012

and Rehabilitation residents, and third- and fourth-year medical

students five times a week.

* In charge of Rheumatology Telemedicine in a weekly bases 2008-2012

(Louisiana Correctional facilities)

* Sub investigator or and Principal investigator in Clinical Trials for 2008-2012

Pfizer, Eli Lilly, Takeda, UCB and Roche

* Translational Research 2007-2013

* Telemedicine Rheumatology 2010-2012
* Reviewer Clinical Rheumatology

**Pharma Experience:**

Design Phase II-III clinical protocols with targeted therapies (large and small molecules), create and carry out strategic plans, Ad boards presentations and planning, teaching role in autoimmune inflammatory conditions to different functions within the company, involved in regulatory (FDA, EMEA) and PRA(NICE, GBA) documents as well as face to face meetings; strong participation in marketing strategic activities and PROs

Experience in Phases II-III of clinical drug development, global patient safety, and life cycle management for biologic therapies in autoimmune indications, and involved in the implementation of global phase 3 program with a lead indication in Spondyloarthropathies i.e. Psoriatic Arthritis.

**Sub investigator (SI) in Clinical Trials for Pfizer, Roche and Takeda:**

1. A prospective, observational study to evaluate the long-term safety and functional status of subjects with subjects with Rheumatoid Arthritis previously enrolled in studies of CP-690,550 (A3921029) **Pfizer (SI)**
2. A randomized, double-blind, parallel-group study to evaluate the safety and efficacy of tocilizumab (TCZ) versus placebo in combination with Disease Modifying Anti rheumatic Drugs (DMARDs**)** in patients with moderate to severe active rheumatoid arthritis (RA)

Protocol No. ML21136/D **Roche (SI)**

1. An open-label, randomized study to evaluate the safety, tolerability and efficacy of tocilizumab (TCZ) monotherapy or TCZ in combination with non-biologic disease modifying anti rheumatic drugs (DMARDs) in patients with active rheumatoid arthritis who have an inadequate response to current non-biologic or biologic DMARDs

Protocol Number: ML22533/B**Roche (SI)**

1. Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of 2 Doses of CP-690,550 in Patients with Active Rheumatoid Arthritis On Background Methotrexate with Inadequate Response to TNF inhibitors. A3921032 **Pfizer (SI)**
2. A Long Term Open Label Follow up Study of CP-690,550 of Tofacitinib (cp‑690,550) for Treatment Rheumatoid Arthritis Protocol # A3921024 **Pfizer (SI)**
3. Phase 3 Randomized, Double-Blind Study of the Efficacy and Safety of 2 Doses of CP-690-550 compared to Methotrexate in Methotrexate Naïve Patients with Rheumatoid Arthritis Protocol # A3921069 **Pfizer (SI)**
4. A Multicenter, Randomized, Active-Control, Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Subjects with Gout and Cardiovascular Comorbidities. Protocol # TMX-67\_301 **Takeda (SI)**
5. Psoriatic Arthritis Foremost study

**Presentations:**

1. American College of Rheumatology 2017 Knowledge Bowl, 3rd place
2. American College of Rheumatology 2016 Knowledge Bowl
3. Kim Papp, Catherine Shuler, **Raquel Cuchacovich**, Hua Wei, Michael Heffernan. The effects of ixekizumab treatment in a subset of patients with psoriatic arthritis in a phase 2 study in moderate-to-severe plaque psoriasis. EADV 2014
4. Perez-Alamino R, **Cuchacovich RS**, Tate DJ, Patterson JR, Porretta C, Erbil J, Martinez C, Zea AH, Espinoza LR. Role of Inflammasome Activation in Systemic Lupus Erythematosus: are innate immune cells activated? ACR 2014
5. Perez-Alamino R, **Cuchacovich RS**, Zea AH, Espinoza LR. Is there a role of Inflammasome activation in PsA pathogenesis and its comorbidities? ACR 2014 and GRAPPA meeting 2104
6. **Cuchacovich R**, et al. Association of Osteoprotegerin (OPG) and Ligands in Psoriatic Arthritis (PsA) Patients without Cardiovascular (CV) Events. GRAPPA meeting, December 2010; and Southern Meeting AFMR. 2011. New Orleans, Louisiana.
7. **Cuchacovich R**. Clinical Evidence Regarding Cardiovascular Prevention in Connective-Tissue Diseases. PANLAR, April 2010.
8. **Cuchacovich R**. Medicine Grand Rounds “Clinical Significance of Hyperuricemia” LSU Health Sciences Center, New Orleans, Louisiana, May 2009
9. Visiting Professor: Mexico, June 2009:
   1. Cardiovascular Risk in Connective-Tissue Diseases. Colegio Mexicano de Reumatologia, Mexico City.
   2. Targeting the Neuro-Endocrine and Immune System in Autoimmune Connective Tissue Diseases by Neuropeptides and Neuropeptide-Toxin Complex. ColegioMexicano de ReumatologiaCapitulo Jalisco.
   3. Clinical Significance of Hyperuricemia. Universidad de Guadalajara and Hospital General de Mexico.
   4. Bone Turnover, TNF Blockers in Spondyloarthropathies. InstitutoMexicanodelSeguro Social Mexico City and Universidad Autonoma de San Luis.
10. **Cuchacovich R**. Immunopathogenesis of Large-Vessel Vasculitis. PANLAR 2002 (Aruba).
11. **Cuchacovich R**. Autoimmunity. CongresoChileno de Reumatologia, 1997.
12. **Cuchacovich R**. Cryoglobulinemia. CongresoChileno de Reumatologia. 1997.
13. **Cuchacovich R**. Protein Electrophoresis and Autoimmunity. Course: Electroforesis de Proteinassericas y Lipoproteinas en diferentesfluidosbiologicos.Universidad de Chile, 1997.
14. **Cuchacovich R**. Cryoglobulins y Cryoglobulinemias. VI Congreso Internacional de Rheumatologia del Cono Sur. I Congreso Paraguayo de Alergia e Imunologia, 1995.
15. **Cuchacovich R**. Autoimmunity and Stress. Course: Stress and Immunology. Universidad de Chile, 1994.
16. **Cuchacovich R**, Varas MA. Anti-endothelial Cell Antibodies in Renal Transplant and Graft Outcome. XVI Congreso Chileno de Medicina Interna, 1994.
17. **Cuchacovich R**, VarasMA. Antibodies in Deep Vein Thrombosis. XV Congreso de MedicinaInterna/ XI Congreso Latinoamericano de BioquimicaClinica / XVI CongresoNacional de BioquimicaClinicaMexico,1993.
18. **Cuchacovich R**, Varas MA. Anti-endothelial Cell Antibodies in DVT. III CongresoALAI, 1993.
19. **Cuchacovich R**. Experimental Model: Influence of Stress on Physiological Parameters. Presentation at University of Arizona/ Octavas Jornadas Bienales Medicina Interna Hospital San Juan de Dios, 1992.

**Publications:**

**Peer-Reviewed Journal Articles**

1. Mease PJ, van der Heijde D, Ritchlin CT, Okada M, **Cuchacovich RS**, Shuler CL, Lin CY, Braun DK, Lee CH, Gladman DD; SPIRIT-P1 Study Group. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis. 2016 Aug 23. pii: annrheumdis-2016-209709. doi: 10.1136/annrheumdis-2016-209709
2. **Cuchacovich R**, Perez-Alamino R, Zea AH, Espinoza LR. Distinct genetic profile in peripheral blood mononuclear cells of psoriatic arthritis patients treated with methotrexate and TNF-inhibitors. Clin Rheumatol. 2014 Dec; 33(12):1815-21.
3. Perez-Alamino R, Garcia-Valladares I**, Cuchacovich R**, Iglesias-Gamarra A, Espinoza LR.Are anti-CCP antibodies in psoriatic arthritis patients a biomarker of erosive disease? *Rheumatol Int.* 2014 Feb 11
4. **Cuchacovich R**, Garcia-Valladares I, Espinoza LR.Steps in the management of Psoriatic Arthritis (PsA): A guide for clinicians*. Therapeutic Advances in Chronic Diseases* (Invited review). TherAdv Chronic Dis. 2012 Nov;3(6):259-69
5. **Cuchacovich R**, Espinoza LR. Antihypertensive therapy and incident gout.*International Journal of Clinical Rheumatology*. 2012. In Press
6. **Cuchacovich R**, Garcia-Valladares I, Espinoza LR. [Combination biologic treatment of refractory psoriasis and psoriatic arthritis.](http://0-www.ncbi.nlm.nih.gov.innopac.lsuhsc.edu/pubmed/22210681)*J Rheumatol*. 2012. 39(1):187-93.
7. **Cuchacovich R**, Perez-Alamino R, Garcia-Valladares I, Espinoza LR.
8. Steps in the management of psoriatic arthritis: a guide for clinicians. Ther Adv Chronic Dis. 2012 Nov;3(6):259-69. doi: 10.1177/2040622312459673.
9. Garcia-Valladares I, **Cuchacovich R**, Espinoza LR. [Psoriatic arthritis: radiographic joint repair following etanercept therapy.](http://0-www.ncbi.nlm.nih.gov.innopac.lsuhsc.edu/pubmed/22210679)*J Rheumatol*. 2012 Jan;39(1):185;
10. **Cuchacovich R**, Garcia-Valladares I, Espinoza LR. Cutaneous lesions from IFN-α induced sarcoidosis : how do we reverse the effects? *Expert Review of Dermatology*. 2011. 6(6):551-553
11. **Cuchacovich R**, Garcia-Valladares I, Espinoza LR. Pleiotropic Effects of Inflammasome Modulation in Chronic Gout and Associated Co-morbidities: Potential Therapeutic Implications. *International Journal of Clinical Rheumatology*. 2011. 6(6):669-676.
12. Khan T, **Cuchacovich R**, Espinoza LR, Lata S, Patel N, Garcia-Valladares I, Salassi M, Sanders CV. Vasculopathy, hematological and immune abnormalities associated with Levamisole-contaminated cocaine use. *Seminars in Arthritis and Rheumatism*. 2011. In Press
13. Garcia-Valladares I, **Cuchacovich R,** Espinoza LR.Comparative assessment of biologics in treatment of psoriasis: drug design and clinical effectiveness of ustekinumab. *Drug Des DevelTher*. 2011; 5:41-9
14. **Cuchacovich R**, Hagan J, Khan T, Richert A, Espinoza LR. Tumor Necrosis Factor –alpha (TNF-α) blockade-induced hepatic sarcoidosis in psoriatic arthritis (PsA): Physiopathologic mechanisms and literature review. *Clinical Rheumatology*.2011; 30: 133-137.
15. Cruzat V,**Cuchacovich R,** Espinoza LR. Undifferentiated spondyloarthritis: recent clinical and therapeutic advances. CurrRheumatol Rep. 2010; 12:311-7
16. Karia VR, **Cuchacovich R**, Espinoza LR. Undifferentiated spondyloarthritis following allogenic stem cell transplantation. *MusculoskeletDisord*. 2010 Jun 25; 11(1):132.
17. Gedalia A, **Cuchacovich R**. Systemic vasculitis in childhood. *CurrRheumatol Rep*. 2009; 402:9.
18. **Cuchacovich R**, Gedalia A.Pathophysiology and clinical spectrum of infections in systemic lupus erythematosus (SLE).*Rheumatic Dis Clin North Am*. 2009; 35: 75-93.
19. **Cuchacovich R**, Espinoza LR. Ustekinumab for psoriatic arthritis. *The Lancet*. 2009; 373: 605-606.
20. **Cuchacovich R**, Espinoza LR. Does TNF-alpha blockade play any role in cardiovascular risk among rheumatoid arthritis (RA) patients? *ClinRheumatol*. 2009; 28(10): 1217-1220.
21. **Cuchacovich R**, Virck Z, Espinoza C, Espinoza L. Biologic therapy (TNF-alpha antagonists)-induced psoriasis: A cytokine imbalance between TNF-alpha and IFN-alpha? *J Clin Rheum*. 2008 Dec; 14(6):353-356.
22. Saketkoo L, **Cuchacovich R**, Espinoza L. Methotrexate therapy for psoriatic arthritis: Reappraisal of an old remedy. *J Rheumatol*. 2008; 35 (3): 369-371.
23. Naqvi A, **Cuchacovich R**, Saketkoo L, Espinoza LR. Acute Charcot arthropathy successfully treated with pamidronate: Long-term follow-up. *Am J Sci*. 2008; 35(2): 145-148.
24. Justiniano M, Colmegna I, **Cuchacovich R**, Espinoza LR. Spondyloarthritis as a presentation of gouty arthritis. *J Rheumatol*. 2007; 34(5): 1157-1158.
25. **Cuchacovich R**, Justiniano M, Espinoza LR. Churg-Strauss syndrome associated with leukotriene receptor antagonists (LTRA). *ClinRheumatol*. 2007 October; 26(10): 1769-1771. E-pub January 26, 2007.
26. **Cuchacovich R**. Update on applications of polymerase chain reaction in rheumatology. *Infect Dis Clin North Am*. 2006; 20(4): 735-758.
27. Colmegna I, **Cuchacovich R**, Espinoza LR. HLA-B27-associated reactive arthritis: Pathogenetic and clinical considerations. *ClinMicrobio Rev*. 2004; 17: 348-369.
28. **Cuchacovich R**, Espinoza LR. Lower levels of synovial fluid IFN-alpha in HLA B-27-positive than HLA B-27-negative patients with chlamydia trachomatis reactive arthritis. *Rheumatology*. 2004; 43: 249-250.
29. **Cuchacovich R**, Espinoza LR. Clinical and serological associations of ribosomal P antibodies in systemic lupus erythematosus: A prospective evaluation in a large cohort of Italian patients. *Rheumatology*. 2003; 42: 1-2.
30. **Cuchacovich** R, Quinet S, SantosAM. Applications of polymerase chain reaction in rheumatology. *Rheum Dis Clin North Am*. 2003; 29: 1-19.
31. Singh R,**Cuchacovich R**, Gomez R, Vargas A, Espinoza LR,Gedalia A. Simultaneous occurrence of diabetes mellitus and juvenile dermatomyositis: Report of two cases. *ClinPed*. 2003; 42(5):459-462.
32. Singh R,Menon Y, **Cuchacovich R**, Espinoza LR. A six month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal anti-inflammatory drug-refractory ankylosing spondylitis: comment on the article by Maksymowych et al. *Arthritis Rheum*. 2003; 48: 583-4.
33. **Cuchacovich** R, Calvo A, Vega L, Espinoza LR. Detection of bacterial DNA in Latin American patients by polymerase chain reaction and sequencing. *J Rheum*. 2002; 29: 1426-1429.
34. **Cuchacovich R**. Immunopathogenesis of vasculitis. *Curr Rheum Reports*. 2002; 4(1): 9-17.
35. **Cuchacovich R**. New targets for pharmacologic modulation of the formation and activity of osteoclasts. *Fellow Reporter* (AmericanCollege of Rheumatology). 2002; 7: 25-30.
36. Menon Y, Singh R, **Cuchacovich R**, Espinoza LR. Morbidity not increased in rheumatoid arthritis patient with profound lymphopenia following CD4 monoclonal antibody therapy: Comment on the article by Isaacs et al. *Arthritis & Rheumatism*. 2002 Jul; 46(7):1973-1974; discussion 1974.
37. Singh R, **Cuchacovich R**, Huang W, Menon Y, Espinoza LR. Cerebrovascular disease in systemic lupus erythematosus (SLE): lack of association with anticardiolipin(a CL) antibodies*. J ClinRheumatol*. 2002; 8 : 185-6
38. Menon Y, Singh R, **Cuchacovich R,** Espinoza LR. Pulmonary involvement in hepatitis B-related polyartheritisnodosa. *Chest*. 2002; 122: 1497-8
39. Singh R, **Cuchacovich R**, Huang W, Espinoza LR. Infliximab treatment in a patient with rheumatoid arthritis on hemodialysis. *J Rheum*. 2002; 29(3): 636-637.
40. **Singh R**, **Cuchacovich R**, Espinoza LR. Inclusion body myositis unresponsive to etanercept. *J Clin Rheum*. 2001; 4: 279-280.
41. **Cuchacovich R**, Espinoza LR. Applications of the polymerase chain reaction. *ComiteIberoamericano de ReumatologiaBoletin*.1999; 9: 96-99.
42. **Cuchacovich R**, Varas MA. Gangliosides in immunology. *RevistaChilena de Reumatologia*.1996; 12.
43. **Cuchacovich R**. Auto-antibodies in rheumatology. *RevistaChilena de Reumatologia*. 1996; 12.
44. **Cuchacovich R**, Varas MA. Glangliosides and Autoimmuneconnectivetissuediseases. *Boletin San Juan de Dios*. 1993;40: 152-153.
45. **Cuchacovich R**. Acute phase response, inflammation and tissue reparation. *Series CientificasBasicas. Editorial Mediterraneo*, 1993.
46. **Cuchacovich R**. ANCA. *RevistaChilena de Rheumatologia*. 1992.
47. **CuchacovichR**, Vargas N. Unwanted children in the rural-urban environment: Assay of detection criteria. *RevistaChilena de Pediatria*. 1986; 57: 359-366.

**Letters to the Editor**

1. **Cuchacovich R**, Garcia-Valladares I, Espinoza LR. Combination Biologic Treatment of Refractory Psoriasis (Ps) and Psoriatic Arthritis (PsA): Case report and literature review. *Journal of Rheumatology*. 2011. In Press
2. **Cuchacovich R**, Espinoza LR. Clinical and serological associations of ribosomal P autoantibodies in systemic lupus erythematosus: Evaluation in a large cohort of Italian patients. *Rheumatology*. 2003; 42: 1116-1117.
3. **Cuchacovich R**, Espinoza LR. Soluble TNF receptor treatment does not affect raised TGF-beta levels in RA. *Ann Rheum Dis*. 2002; 61(7):667.
4. **Cuchacovich R**, Espinoza LR. Critical comment of “Improved Medical and Surgical Management of Cervical Spine Disease in patients with RA over 10 years.” *Rheumatoid Arthritis*. 2000;3:11.
5. **Cuchacovich R**, Espinoza LR. Critical comment of “Lytic Epstein-Barr virus infection in the synovial tissue of patients with RA.” *Rheumatoid Arthritis*. 2000; 3: 11.
6. **Cuchacovich R**, Espinoza LR. Critical comment of “Neutrophil function in pregnancy and RA.” *Rheumatoid Arthritis*. 2000; 3: 12.
7. **Cuchacovich R**, Espinoza LR. Critical comment of “Relationship between time-integrated C-reactive protein levels and radiographic progression in patients with RA.” *Rheumatoid Arthritis*. 2000; 3: 13.

**Abstracts**

1. A Randomized, Double-blind, Active- and Placebo-controlled Phase 3 Study of Efficacy and Safety of Ixekizumab, Adalimumab, and Placebo Therapy in Patients Naïve to Biologic Disease modifying Anti-rheumatic Drugs with Active Psoriatic Arthritis. Philip J. Mease; Désirée van der Heijde; Christopher T. Ritchlin; **Raquel S. Cuchacovich**; Catherine L. Shuler; Chen-Yen Lin; Harald Vangerow; Chin H. Lee; Suvajit Samanta; Dafna D. Gladman. ACR 2015
2. Ixekizumab Improves Physical Function, Quality of Life, and Work Productivity in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients with Active Psoriatic Arthritis. Alice B Gottlieb, Philip J Mease, **Raquel Cuchacovich**, Catherine L Shuler, Russel Burge, Suvajit Samanta, Chen-Yen Lin, Chin Lee, Dafna D.Gladman. ACR 2015
3. Alice B Gottlieb, Kim A Papp, Kristina Callis Duffin, Charles A Birbara, **Raquel Cuchacovich**, Catherine L Shuler, Russel Burge, Janelle Erickson, Lisa Kerr, Philip J Mease. Ixekizumab in Patients with Psoriasis and Psoriatic Arthritis: Pooled Analysis of the Three Phase 3 studies in Moderate-to-Severe Psoriasis. 4th World Psoriasis & Psoriatic Arthritis. July 8-11, 2015
4. Kim Papp, Catherine Shuler, Raquel Cuchachovich, Hua Wei, Michael Heffernan. The effects of ixekizumab treatment in a subset of patients with psoriatic arthritis in a phase 2 study in moderate-to-severe plaque psoriasis. EADV 2014
5. Perez-Alamino R, Cuchacovich RS, Tate DJ, Patterson JR, Porretta C, Erbil J, Martinez C, Zea AH, Espinoza LR. Role of Inflammasome Activation in Systemic Lupus Erythematosus: are innate immune cells activated? ACR 2014
6. Perez-Alamino R, Cuchacovich RS, Zea AH, Espinoza LR. Is there a role of Inflammasome activation in PsA pathogenesis and its comorbidities? ACR 2014 and GRAPPA meeting 2104
7. Garcia-Valladares I, **Cuchacovich R**, Iglesias-Gamarra A,Espinoza LR. Are High Titers of Anti-CCP Antibodies in Psoriatic Arthritis Patients a Biomarker of Erosive Disease? ACR/ARHP Meeting 2011. Chicago
8. Garcia-Valladares I, **Cuchacovich R**, Espinoza LR. “Combination biologic therapy for refractory psoriasis and psoriatic arthritis.” American College of Rheumatology Meeting. November 2011. Chicago, IL.
9. **Cuchacovich R**, Garcia-Valladares I, Espinoza LR.“Association of osteoprotegerin (OPG) and ligands in psoriatic arthritis (PsA) patients without cardiovascular (CV) events.” GRAPPA Meeting. December 2010. Miami, Florida/Southern Meeting,AFMR. 2011. New Orleans, Louisiana.
10. Garcia-Valladares I, **Cuchacovich R**, Espinoza LR. “Combination biologic therapy for refractory psoriasis and psoriatic arthritis.” GRAPPA Meeting. December 2010. Miami, Florida.
11. **Cuchacovich R**, Hagan J, Khan T, Espinoza L. “Cardiovascular risk in spondyloarthropathies (SpA) and rheumatoid arthritis (RA) on longstanding TNF-blockers.” Southern Meeting, AFMR. 2010. New Orleans, Louisiana.
12. **Cuchacovich R**, Hagan J, Lata S, Espinoza L.“Do adipocytokines play a role in bone turnover in spondyloarthropathies (SpA)?” Southern Meeting,AFMR. 2010. New Orleans, Louisiana.
13. **Cuchacovich R**, Gedalia A.Pathophysiology and clinical spectrum of infections in systemic lupus erythematosus. Rheum Dis Clin North Am. 2009 Feb;35(1):75-93.https://pubmed-ncbi-nlm-nih-gov.ezproxy.hsc.usf.edu/19480998/
14. LA, **Cuchacovich R**, Espinoza LR. Methotrexate therapy for psoriatic arthritis: reappraisal of an old remedy. Saketkoo J Rheumatol. 2008 Mar;35(3):369-71
15. **Cuchacovich R**, Espinoza LR. “Do TNF-alpha blockers play any role in cardiovascular risk among rheumatoid arthritis patients?” *Arthritis and Rheumatism*, 2006.
16. Gedalia A, **Cuchacovich R**. Systemic vasculitis in childhood.Curr Rheumatol Rep. 2009 Dec;11(6):402-9. doi: 10.1007/s11926-009-0059-4
17. **Cuchacovich R**, Flores D, Gedalia A, Cuchacovich M, Marquez J, Singh R, Thompson H, Menon Y, Vincent M, Scopelitis E, Garza M, Espinoza LR. “Antinucleosome autoantibodies in rheumatoid arthritis (RA) patients treated with methotrexate (MTX) or TNF antagonists: Prevalence, clinical and serological correlations. ACR 66th Annual Scientific Meeting; October 25-29, 2002. Published in *Arthritis and Rheumatism*, 46, Supplement, September 2002.
18. Singh R, Menon Y, **Cuchacovich R**, Espinoza LR, Wilson WA, Gedalia A. “Comparison of childhood- with adult-onset sarcoidosis in patients attending rheumatology clinics. ACR 66th Annual Scientific Meeting; October 25-29, 2002. Published in *Arthritis and Rheumatism*, 46, Supplement, September 2002.
19. Marquez J, Restrepo C, Flores D, **Cuchacovich R**, Gimenez C, Rivas F, Tienman W, Espinoza LR. “Changing clinical spectrum of musculoskeletal complications of HIV infection.” ACR 66th Annual Scientific Meeting, October 25-29, 2002. Published in *Arthritis and Rheumatism*, 46, Supplement, September 2002.
20. **Cuchacovich** R, Calvo A, Espinoza LR. “Detection of bacterial DNA in Latin American patients by polymerase chain reaction and sequencing.” *Arthritis and Rheumatism.*  2001; 44: S 347.
21. **CuchacovichR**, Cuchacovich M, Espinoza LR. “Presence and expression of human endogenous retroviruses in patients with psoriatic arthritis.” *Arthritis and Rheumatism*. 2001;44: S 348.
22. **Singh R**, **Cuchacovich R**, Espinoza LR. “Deregulation of insulin receptor like growth factor-1 and insulin growth factor binding protein–3 leading to hypoglycemia in SLE.” *Arthritis and Rheumatism*. 2001;44: S 335.
23. **Cuchacovich R, Singh R, Cuellar M, Espinoza LR. “**Distinct patterns of gene expression by peripheral blood mononuclear cells of rheumatoid arthritis and psoriatic arthritis patients treated with TNF antagonists or methotrexate.AmericanCollege of Rheumatology 2001 Annual Scientific Meeting.
24. Aziz A, **Cuchacovich R**, Espinoza LR. “Pseudoseptic arthritis presenting as initial manifestation of rheumatoid arthritis. 2001 Southern Meeting AFMR.
25. **Cuchacovich R**, Japa S, Espinoza LR. “Striking association of anti-ribosomal P protein, anti-cardiolipin and beta 2 GPI.”*Arthritis and Rheumatism*. 2000; 43: S312.
26. **Cuchacovich R**, Japa S, Espinoza LR. “Cytokine profile in psoriatic arthritis: Predominance of TH-1-derived proinflammatory cytokines. *Arthritis and Rheumatism*. 2000; 43: S104.